Literature DB >> 35482363

Chimeric Antigen Receptor T-Cell Therapy in Multiple Myeloma-Challenges and Potential Solutions.

Samer Al Hadidi1, Maurizio Zangari1, Frits van Rhee1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2022        PMID： 35482363     DOI： 10.1001/jamaoncol.2022.0319

Source DB:  PubMed          Journal:  JAMA Oncol        ISSN： 2374-2437            Impact factor:   33.006


× No keyword cloud information.
  3 in total

Review 1.  Road testing new CAR design strategies in multiple myeloma.

Authors:  Priyanka S Rana; Elena V Murphy; Jeries Kort; James J Driscoll
Journal:  Front Immunol       Date:  2022-08-09       Impact factor: 8.786

Review 2.  CAR T-Cell Therapy for Patients with Multiple Myeloma: Current Evidence and Challenges.

Authors:  Matthew J Rendo; Jacinth J Joseph; Liem Minh Phan; Christin B DeStefano
Journal:  Blood Lymphat Cancer       Date:  2022-08-29

3.  Geographic and Racial Disparities in Access to Chimeric Antigen Receptor-T Cells and Bispecific Antibodies Trials for Multiple Myeloma.

Authors:  Raghad Alqazaqi; Carolina Schinke; Sharmilan Thanendrarajan; Maurizio Zangari; John Shaughnessy; Fenghuang Zhan; Guido Tricot; Frits van Rhee; Samer Al Hadidi
Journal:  JAMA Netw Open       Date:  2022-08-01
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.